Understand the source comparison
Comparison Table: 5-Amino-1MQ Stacking Compatibility
GLP-1 Agonists (semaglutide, tirzepatide) Satiety signaling, gastric emptying None. Targets GLP-1 receptors vs NNMT enzyme Any timing (long half-life) High Complementary mechanisms. One reduces intake, other increases oxidation Growth Hormone Secretagogues (CJ
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GLP-1 Agonists (semaglutide, tirzepatide)
- Satiety signaling, gastric emptying
- None. Targets GLP-1 receptors vs NNMT enzyme
- Any timing (long half-life)
- High
- Complementary mechanisms. One reduces intake, other increases oxidation
- Growth Hormone Secretagogues (CJC-1295, ipamorelin)
- Endogenous GH release
- Minimal. IGF-1 downstream may conflict
- 8–12 hour spacing
- Moderate
- Space doses to avoid GH/IGF-1 peak during NNMT inhibition peak
- Tissue Repair Peptides (BPC-157, TB-500)
- Angiogenesis, tissue healing
- None. Independent pathways
- Any timing
- No metabolic pathway conflict. Safe concurrent use
- Thyroid Hormones (T3, T4)
- Thyroid receptor agonism
- None. Different metabolic lever
- Morning for both (standard)
- Both increase metabolic rate. Monitor cumulative cardiovascular load
- Nootropic Peptides (Dihexa, Cerebrolysin)
- Neuroplasticity, BDNF modulation
- None. CNS vs metabolic pathways
- Mechanisms don't intersect. No known interaction risk